Zafgen Inc. | Mutual Funds
Mutual Funds that own Zafgen Inc.
Fidelity Select Biotechnology Portfolio
2,712,346
7.37%
0
0.28%
07/31/2018
Vanguard Total Stock Market Index Fund
805,863
2.19%
50,000
0%
07/31/2018
Fidelity Advisor Biotechnology Fund
491,990
1.34%
-864,184
0.16%
07/31/2018
iShares Russell 2000 ETF
477,796
1.3%
-255
0.01%
09/06/2018
Royce Micro Cap Trust
465,381
1.26%
0
0.96%
06/30/2018
Vanguard Extended Market Index Fund
434,269
1.18%
66,600
0.01%
07/31/2018
iShares Russell 2000 Growth ETF
210,589
0.56%
0
0.02%
09/06/2018
Candriam Equities L - Biotechnology
189,000
0.51%
94,000
0.13%
07/31/2018
DFA US Small Cap Portfolio
184,774
0.5%
61,233
0.01%
04/30/2018
Fidelity Spartan Extended Market Index Fund
148,175
0.4%
47,664
0.01%
07/31/2018
| Address |
175 Portland Street
Boston Massachusetts 02114
United States
|
|
Employees
|
- |
| Website |
http://www.zafgen.com |
| Updated |
07/08/2019 |
| Zafgen, Inc. is a biopharmaceutical company, which is engages in the development of therapeutics for both rare and prevalent metabolic diseases including type 2 diabetes, Prader-Willi syndrome, or PWS, and potentially other metabolically related disorders. It offers the ZGN-1061, a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is currently being profiled for its utility in the treatment of type 2 diabetes. The company was founded on November 22, 2005 and is headquartered in Boston, MA. |
